Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Description

This study is a double-blind, randomized, prospective, placebo-controlled single-center clinical research study in which 600 mg of gabapentin or placebo will be administered 2 hours preoperatively to 49 patients each undergoing wisdom teeth extraction. We will measure intraoperative opioid use, severity of pain, the number of analgesics taken, and side effect profiles (e.g. nausea/vomiting, dizziness) at the following intervals, 4 hour, 8 hour, 12 hour, 24, and 72 hour post-procedure.

Conditions

Dental Pain and Sensation Disorder, Pain, Postoperative

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is a double-blind, randomized, prospective, placebo-controlled single-center clinical research study in which 600 mg of gabapentin or placebo will be administered 2 hours preoperatively to 49 patients each undergoing wisdom teeth extraction. We will measure intraoperative opioid use, severity of pain, the number of analgesics taken, and side effect profiles (e.g. nausea/vomiting, dizziness) at the following intervals, 4 hour, 8 hour, 12 hour, 24, and 72 hour post-procedure.

Efficacy of Preoperative Administration of Gabapentin in Managing Intraoperative and Postoperative Pain From Third Molar Extractions.

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Condition
Dental Pain and Sensation Disorder
Intervention / Treatment

-

Contacts and Locations

Loma Linda

Loma Linda University Health, Loma Linda, California, United States, 92354

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects must be at or older than 18.
  • * Screened body mass index (BMI) between 18-35 kg/m2.
  • * American Society of Anesthesiologists Classification I and II.
  • * Subjects must be willing and able to comply with protocol requirements.
  • * Subjects must be able to understand the informed consent and must be able to sign a written informed consent form prior to the initiation of any study procedures.
  • * A subject must have at least 1 partial or fully impacted third molar tooth removal.
  • * hypersensitivity to gabapentinoids;
  • * history of chronic opioid or gabapentin usage (regular use of opioids \>3 months)
  • * history of recreational drug usage
  • * a history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, musculoskeletal, psychiatric, or immunologic disorder, any acute, clinically significant illness or condition within 14 days prior to Day 1.
  • * Patients with baseline pain.
  • * Patients with any oral pathology will be excluded.
  • * Pregnant or breastfeeding patients
  • * An individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors)

Ages Eligible for Study

18 Years to 59 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Loma Linda University,

Chi Viet, DDS MD PhD, PRINCIPAL_INVESTIGATOR, Loma Linda University

Study Record Dates

2025-07